These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 10831022

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Pharmacokinetics of methylphenidate and ritalinic acid in plasma correlations with exhaled breath and oral fluid in healthy volunteers.
    Arvidsson M, Dahl ML, Beck O, Ackehed G, Nordin K, Rosenborg S.
    Eur J Clin Pharmacol; 2020 Feb; 76(2):229-237. PubMed ID: 31786618
    [Abstract] [Full Text] [Related]

  • 7. The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans.
    Capon DA, Bochner F, Kerry N, Mikus G, Danz C, Somogyi AA.
    Clin Pharmacol Ther; 1996 Sep; 60(3):295-307. PubMed ID: 8841152
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics of dextromethorphan and metabolites in humans: influence of the CYP2D6 phenotype and quinidine inhibition.
    Schadel M, Wu D, Otton SV, Kalow W, Sellers EM.
    J Clin Psychopharmacol; 1995 Aug; 15(4):263-9. PubMed ID: 7593709
    [Abstract] [Full Text] [Related]

  • 9. Involvement of CYP2D6 activity in the N-oxidation of procainamide in man.
    Lessard E, Hamelin BA, Labbé L, O'Hara G, Bélanger PM, Turgeon J.
    Pharmacogenetics; 1999 Dec; 9(6):683-96. PubMed ID: 10634131
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of debrisoquine hydroxylation with quinidine in subjects with three or more functional CYP2D6 genes.
    Dalén P, Dahl M, Andersson K, Bertilsson L.
    Br J Clin Pharmacol; 2000 Feb; 49(2):180-4. PubMed ID: 10671914
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension.
    Zineh I, Beitelshees AL, Gaedigk A, Walker JR, Pauly DF, Eberst K, Leeder JS, Phillips MS, Gelfand CA, Johnson JA.
    Clin Pharmacol Ther; 2004 Dec; 76(6):536-44. PubMed ID: 15592325
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults.
    Markowitz JS, Straughn AB, Patrick KS, DeVane CL, Pestreich L, Lee J, Wang Y, Muniz R.
    Clin Pharmacokinet; 2003 Dec; 42(4):393-401. PubMed ID: 12648029
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety.
    Samer CF, Daali Y, Wagner M, Hopfgartner G, Eap CB, Rebsamen MC, Rossier MF, Hochstrasser D, Dayer P, Desmeules JA.
    Br J Pharmacol; 2010 Jun; 160(4):919-30. PubMed ID: 20590588
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.